Opus Genetics (IRD) Operating Margin (2010 - 2026)
Opus Genetics (IRD) posted quarterly Operating Margin of 665.92% for Q1 2026, down 43872.0% year-over-year from N/an in Q1 2025, and down 124.73% quarter-over-quarter from 296.33% in Q4 2025.
Opus Genetics (IRD) Operating Margin (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Operating Margin for 8 consecutive years, with 665.92% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin fell 43872.0% year-over-year to 665.92%; the TTM figure through Mar 2026 stood at 359.13% (up 11187.0% YoY), while the FY2025 annual figure was 271.9%, up 29282.0% from the prior year.
- Operating Margin eased to 665.92% in Q1 2026 per IRD's latest filing, from 296.33% in the prior quarter.
- Across five years, Operating Margin topped out at 85.85% in Q4 2022 and bottomed at 883.98% in Q4 2024.
- Historically, Operating Margin has averaged 338.42% across 5 years, with a median of 302.67% in 2025.
- Annual changes were most pronounced in 2024 — Operating Margin slumped 60224 bps — and 2025, when it soared 58766 bps.
- Opus Genetics' Operating Margin stood at 85.85% in 2022, then slumped by 474 bps to 321.05% in 2023, then plunged by 175 bps to 883.98% in 2024, then jumped by 66 bps to 296.33% in 2025, then plunged by 125 bps to 665.92% in 2026.
- Business Quant data shows IRD's Operating Margin at 665.92% in Q1 2026, 296.33% in Q4 2025, and 269.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -2,182.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,182.78% |
| Mar 31, 2026 | -665.92% |
| Dec 31, 2025 | -296.33% |
| Sep 30, 2025 | -269.93% |
| Jun 30, 2025 | -309.02% |
| Mar 31, 2025 | -227.21% |
| Dec 31, 2024 | -883.98% |
| Sep 30, 2024 | -207.11% |
| Jun 30, 2024 | -748.92% |
| Mar 31, 2024 | -450.50% |
| Dec 31, 2023 | -321.05% |
| Sep 30, 2023 | 53.51% |
| Jun 30, 2023 | -146.68% |
| Mar 31, 2023 | -350.54% |
| Dec 31, 2022 | 85.85% |
| Sep 30, 2021 | -865.44% |
| Jun 30, 2021 | -7,137.00% |
| Mar 31, 2020 | -237.83% |
| Jun 30, 2010 | -17,008.07% |